The economic burden of COPD

Chest

Volumn 117, Issue 2 SUPPL., 2000, Pages 5S-9S

  Sullivan, Sean D ^a   Ramsey, Scott D ^a   Lee, Todd A ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

COPD; Pharmacoeconomics

Indexed keywords

ANTIINFLAMMATORY AGENT; BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; IPRATROPIUM BROMIDE; SALBUTAMOL; TERBUTALINE; THEOPHYLLINE;

CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; HEALTH CARE COST; HOSPITAL DISCHARGE; HOSPITALIZATION; LENGTH OF STAY; PRIORITY JOURNAL; REVIEW; UNITED STATES;

EID: 0033998254     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.117.2_suppl.5S     Document Type: Article

References (26)

1. Division of Epidemiology, National Heart, Lung, and Blood Institute, 1996; Available at http://www.nhlbi.nih.gov
2. National Center for Health Statistics, National Health Interview Survey, 1993
3. Sullivan SD, Strassels SA, Smith DH. Characterization of the costs of chronic obstructive pulmonary disease (COPD) in the US [abstract]. Eur Respir J 1996; 9(suppl 23):421S
4. Grasso ME, Weller WE, Shaffer TJ, et al. Capitation, managed care, and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 158:133-138
5. Office of National Statistics. Mortality statistics (revised) 1994: England and Wales. London, UK: Her Majesty's Stationery Office, 1996
6. National Health Service Executive. Burdens of disease: a discussion document. Leeds, United Kingdom; Department of Health, 1996
7. Lofdahl CG. Cost development of obstructive airway disease in Sweden. Eur Respir Rev 1996; 6:113-115
8. Sclar DA, Legg RF, Skaer TL, et al. Ipratropium bromide in the management of chronic obstructive pulmonary disease: effect on health service expenditures. Clin Ther 1994; 16: 595-601
9. Tengs TO, Adams ME, Pilskin JS, et al. Five hundred life saving interventions and their cost-effectiveness. Risk Anal 1995; 15:369-390
10. Parrott S, Godfrey C, Raw M, et al. Guidance for commissioners on the cost effectiveness of smoking cessation interventions. Thorax 1998; 53(suppl 5):S1-38
11. Petty TL, O'Donohue WJ Jr. Further recommendations for prescribing, reimbursement, technology development, and research in long-term oxygen therapy: summary of the Fourth Oxygen Consensus Conference, Washington, DC, October 15-16, 1993. Am J Respir Crit Care Med 1994; 150:875-877
12. Pelletier-Fleury N, Lanoe JL, Fleury B, et al. The cost of treating COPD patients with long-term oxygen therapy in a French population. Chest 1996; 110:411-416
13. Ries AL, Kaplan RM, Limberg TM, et al. Effects of pulmonary rehabilitation on physiologic and psychological and psychosocial outcomes in patients with chronic obstructive pulmonary disease. Ann Intern Med 1995; 122:823-832
14. Folgering H, Rooyakkers J, Herwaarden C. Education and cost/benefit ratios in pulmonary patients. Monaldi Arch Chest Dis 1994; 49:166-168
15. Goldstein RS, Gort EH, Guyatt GH, et al. Economic analysis of respiratory rehabilitation. Chest 1997; 112:370-379
16. Ries AL. Position paper of the American Association of Cardiovascular and Pulmonary Rehabilitation: scientific basis of pulmonary rehabilitation. J Cardiopulm Rehabil 1990; 10:418-441
17. Huizenga HF, Ramsey SD, Albert RK. Estimated growth of lung volume reduction surgery among Medicare enrollees: 1994-1996. Chest 1998; 114:1583-1587
18. Gentry C. Second opinion: why Medicare covers a new lung surgery for just a few patients. Wall Street Journal, June 29, 1998; section A, p1
19. Elpern EH, Behner KG, Klontz B, et al. Lung volume reduction surgery: an analysis of hospital costs. Chest 1998; 113:896-899
20. Albert RK, Lewis S, Wood D, et al. Economic aspects of lung volume reduction surgery. Chest 1996; 110:1068-1071
21. Ramsey SD, Patrick DL, Albert RK, et al. The cost-effectiveness of lung transplantation: a pilot study. Chest 1995; 108:1594-1601
22. Gartner SH, Sevick MA, Keenan RJ, et al. Cost-utility of lung transplantation: a pilot study. J Heart Lung Transplant 1997; 16:1129-1134
23. Al MJ, Koopmanschap MA, van Enckevort PJ, et al. Cost-effectiveness of lung transplantation in the Netherlands: a scenario analysis. Chest 1998; 113:124-130
24. Rutten-van Mölken MP, van Doorslaer EK, Jansen MC, et al. Costs and effects of inhaled corticosteroids and bronchodilators in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 151:975-982
25. Jubran A, Gross N, Ramsdell, J, et al. Comparative cost-effectiveness analysis of theophylline and ipratropium bromide in chronic obstructive pulmonary disease: a three center study. Chest 1993; 103:678-684
26. Friedman M, Serby CW, Mejoge SS, et al. Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD. Chest 1999; 115:635-641